Table 1.
Baseline characteristics of patients (N = 54)
| Characteristic | Cohort A (n = 37) | Cohort B (n = 17) |
|---|---|---|
| Age, years | ||
| Median | 64.0 | 64.0 |
| Range | 43.0-83.0 | 33.0-76.0 |
| Sex, n (%) | ||
| Female | 17 (46.0) | 5 (29.4) |
| Male | 20 (54.1) | 12 (70.6) |
| ECOG performance status, n (%) | ||
| 0 | 24 (64.9) | 9 (52.9) |
| 1 | 13 (35.1) | 8 (47.1) |
| Primary tumour site, n (%) | ||
| Left colon | 16 (43.2) | 6 (35.3) |
| Right colon | 10 (27.0) | 3 (17.7) |
| Transverse colon | 1 (2.7) | 0 (0) |
| Othera | 1 (2.7) | 0 (0) |
| Rectum | 9 (24.3) | 8 (47.1) |
| Disease duration, years | ||
| Median | 2.2 | 1.8 |
| Range | 0.4-11.5 | 0.5-6.5 |
| Time from diagnosis to first metastasis, months | ||
| Median | 14.1 | 10.0 |
| Range | 1.3-107.8 | 0.7-67.3 |
| Prior number of regimens for advanced disease | ||
| Mean ± standard deviation | 1.78 ± 1.11 | 2.35 ± 1.54 |
| Prior systemic anticancer agent, n (%)b | ||
| Fluorouracil | 36 (97.3) | 17 (100) |
| Capecitabine | 10 (27.0) | 8 (47.1) |
| Irinotecan | 35 (94.6) | 16 (94.1) |
| Bevacizumab | 21 (56.8) | 9 (52.9) |
| Cetuximab | 8 (21.6) | 7 (41.2) |
| Panitumumab | 3 (8.1) | 3 (17.6) |
| Oxaliplatin | 14 (37.8) | 6 (35.3) |
ECOG, Eastern Cooperative Oncology Group.
a
In one patient the primary tumour site was the caecum.
b
Agents used in >2% of all patients are listed.